ATLANTA, GA – – (Globe Newswire – August 30, 2024) – – A shareholder class action lawsuit has been filed against Outset Medical, Inc. (“Outset Medical” or “the Company”) (NASDAQ: OM). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts about the Company’s business, operations, and prospects, including allegations that: (1) the Tablo products were marketed for continuous renal replacement therapy, which is not one of the indications approved by the FDA; (2) as a result, Outset Medical was reasonably likely to submit an additional 510(k) application for the Tablo products; (3) there was a substantial risk that the Company would cease sales of the Tablo products pending FDA approval of additional indications; (4) Outset Medical lacked the sales team and process to execute on the ramp of Tablo sales; and (5) as a result of the foregoing, the Company’s revenue growth would be adversely impacted.

If you bought shares of Outset Medical between August 1, 2022 and August 7, 2024, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/outset-medical/ to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is October 28, 2024.